Investor Presentation First Nine Months of 2023
23
Investor presentation
First nine months of 2023
Sales growth of 33%, driven by the GLP-1 portfolio for diabetes
and obesity treatment
Novo NordiskⓇ
DKK
billion
70
Novo Nordisk reported quarterly sales
by therapy
560
Reported sales
CAGR1: 10.5%
60
Reported sales for the first
nine months of 2023
Rare Other
Rare endocrine rare
blood disorders disease
Reported sales and growth breakdown for
the first nine months of 2023
Therapy
Sales
(mDKK)
Growth
Share of
growth
Injectable GLP-12
72,531
44%
54%
RybelsusⓇ
12,840
82%
14%
disorders
1%
50
Total GLP-1
85,371
49%
68%
-5.4%¹
5%2%
Obesity
Total insulin³
36,042
-7%
-6%
40
40
-10.6%1
care
18%
Other Diabetes care4
1,990
-21%
-1%
2.7%1
Total Diabetes care
123,403
25%
60%
30
Obesity care5
30,403
174%
47%
12.4 %1
20
Diabetes and Obesity care
153,806
40%
107%
Rare blood disorders6
8,842
2%
0%
74%
10
Diabetes care
0
Q3
Other rare disease
2013
Rare endocrine disorders
Q3
2023
Rare endocrine disorders?
Other Rare disease
Rare disease
Total
2,572
-54%
-7%
1,178
-7%
0%
12,592
-18%
-7%
166,398
33%
100%
Rare blood disorders
Diabetes and Obesity care
Sales of DKK 166.40 billion
(~33%)
1 CAGR for 10-year period; 2 Comprises Victoza®, Ozempic®; 3 Comprises Tresiba®, XultophyⓇ and Levemir®, RyzodegⓇ and NovoMix®,FiaspⓇ and Novo RapidⓇ: 4 Primarily NovonormⓇ, needles and Gluca Gen® HypoKitⓇ;
5 Comprises SaxendaⓇ and Wegovy®: 6 Comprises NovoSeven®, Novo Eight®, NovoThirteenⓇ Refixia®, and Esperoct®; 7 Comprises NorditropinⓇand Macrilen TM; 8 Primarily VagifemⓇ and ActivelleⓇ
Note: Sales numbers are reported in Danish kroner; Growth is at constant exchange rate, except for total sales growth of 29%; Refixia® and NovoThirteenⓇ are launched as RebinynⓇ and TRETTENⓇ, respectively, in North America.View entire presentation